DISCOVER OUR PIONEERING CONTRIBUTIONS TO ONCOLOGY THROUGH PRESTIGIOUS JOURNALS AND PLATFORMS LIKE ASCO, ESMO, AND SABCS. ELEVATE YOUR INSIGHTS WITH OUR CUTTING-EDGE CLINICAL TRIAL PUBLICATIONS.
EMPOWERING PROGRESS: ONCOLOGY CLINICAL TRIALS SPOTLIGHT
PUBLICATIONS
THE ULTIMATE GOAL OF MEDSIR PROJECTS IS THE PUBLICATION OF ITS STUDY RESULTS, WHETHER IN PEER-REVIEWED JOURNALS OR AT A NUMBER OF NATIONAL AND INTERNATIONAL CONFERENCES IN THE FORM OF ABSTRACTS, POSTERS, OR ORAL PRESENTATIONS.
STUDY
OFFICIAL TITLE
DISEASE
JOURNAL/
CONGRESS
YEAR
DOWNLOAD
MIRROR
Evaluation of a Generative Artificial Intelligence (AI) and Natural Language Processing (NLP) tool to obtain clinical data from electronic health records (EHRs) versus manual data capture in Oncology Clinical Trials: The MIRROR study.
BREAST
AIME
2024
PHERGAIN
Clinicopathological and molecular predictors of [18F]FDG-PET disease detection in HER2-positive early breast cancer: RESPONSE, a substudy of the randomized PHERGain trial
BREAST
(Journal) European Journal of Nuclear Medicine and Molecular Imaging
2024
PHERGAIN
Correlation between trophoblast cell-surface antigen-2 (Trop-2) expression and
pathological complete response (pCR) in HER2-positive early breast cancer (EBC):
An exploratory analysis of the PHERGain trial
BREAST
(Journal) Breast Cancer Research and Treatment
2024
LUZERN
LUZERN: Phase 2 trial of niraparib and aromatase inhibitors (AI) for pretreated hormone receptor-positive/HER2-negative germline BRCA-mutated advanced breast cancerRN: Phase 2 trial of niraparib and aromatase inhibitors (AI) for pretreated hormone receptor-positive/HER2-negative germline BRCA-mutated advanced breast cancer
BREAST
ESMO Breast
2024
PRIMED
Prevention of sacituzumab govitecan (SG)-related neutropenia and diarrhea in patients (pts) with triple-negative or HR+/HER2- advanced breast cancer (ABC; PRIMED): A phase 2 trial.
BREAST
ASCO
2024
ADELA
Double-blind, Placebo-controlled, Randomized Phase 3 Trial of Elacestrant (ELA) + Everolimus (EVE) Versus ELA + Placebo (PBO) in ER+/HER2- Advanced Breast Cancer (aBC) Patients (pts) with ESR1-mutated Tumors Progressing on Endocrine Therapy (ET) + CDK4/6i
BREAST
SABCS
2024
RESPONSE
Clinicopathological and Molecular Predictors of [18F]FDG-PET Disease Detection in HER2-Positive Early Breast Cancer: RESPONSE, a substudy of the randomized PHERGain Trial
BREAST
Eur J Nucl Med Mol Imaging
2024
PARSIFAL
Impact of coadministration of proton-pump inhibitors and palbociclib in hormone receptor-positive/HER2-negative advanced breast cancer
BREAST
(Journal) The Breast
2024
PECATI
PECATI: A phase 2 trial to evaluate the efficacy and safety of lenvatinib in combination with pembrolizumab in pretreated advanced B3-thymoma and thymic carcinoma
THYMIC
ESMO
2024
ZZ-FIRST
First results from ZZFIRST: a randomized phase II trial of enzalutamide (EZ) with or without talazoparib (TALA) in metastatic hormone-naïve prostate cancer (mHNPC)
PROSTATE
ESMO
2024
PHERGAIN
SUBSTUDY - Trop-2: Correlation between trophoblast cell-surface antigen-2 (Trop-2) expression and pathological complete response in patients with HER2-positive early breast cancer treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab
BREAST
Breast Cancer Research and Treatment
2024
PHERGAIN
SUBSTUDY - HER2DX: HER2DX Genomic Assay in HER2-positive Early Breast Cancer Treated with Trastuzumab and Pertuzumab: A Correlative Analysis from PHERGain Phase II Trial
BREAST
Clinical Cancer Research
2024
Other MEDSIR related articles
"